Use of HSV vectors to modify the nervous system

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 2, 2002, Pages 289-295

  Glorioso, Joseph C ^a   Fink, David J ^a  

^a VA Healthcare VISN 4   (United States)

Author keywords

Gene transfer; HSV; Pain; Parkinson's disease; Peripheral nervous system diseases

Indexed keywords

VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; GENE DISRUPTION; GENE EXPRESSION; GENE FUNCTION; GENE TRANSFER; HERPES SIMPLEX VIRUS; HUMAN; NERVE DEGENERATION; NEUROLOGIC DISEASE; NONHUMAN; PAIN; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; RAT; REVIEW; TRANSGENE; VIRUS REPLICATION;

ANIMALS; CLINICAL TRIALS; GENE THERAPY; GENETIC VECTORS; HUMANS; NERVOUS SYSTEM DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; SIMPLEXVIRUS; TRANSGENES;

EID: 0036489853     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Gene transfer to neurons using herpes simplex virus-based vectors
2. Engineering herpes simplex virus vectors for CNS applications
3. A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats
4. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4
5. Rapid method for construction of recombinant HSV gene transfer vectors
6. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons
7. PCR-based analysis of herpes simplex virus type 1 latency in the rat trigeminal ganglion established with a ribonucleotide reductase-deficient mutant
8. Competitive quantitative PCR analysis of herpes simplex virus type 1 DNA and latency-associated transcript RNA in latently infected cells of the rat brain
9. Detection of herpes simplex virus type 1 latency-associated transcript expression in trigeminal ganglia by in situ reverse transcriptase PCR
10. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat
11. Bcl-2 and GDNF delivered by HSV-mediated gene transfer act addictively to protect dopaminergic neurons from 6-OHDA induced degeneration
12. Herpes simplex virus vector-mediated expression of Bcl-2 protects spinal motor neurons from degeneration following root avulsion
13. Bcl-2 and GDNF delivered by HSV-mediated gene transfer after spinal root avulsion provide a synergistic effect
14. Neurotrophin-3 administration attenuates deficits of pyridoxine-induced large-fiber sensory neuropathy
15. In vivo gene therapy for pyridoxine-induced neuropathy by HSV-mediated gene transfer of neurotrophin-3
16. Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus
17. Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons
18. Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion
19. The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats
20. Drug inducible transgene expression in brain using a herpes simplex virus vector
21. Improved methods of retroviral vector transduction and production for gene therapy
22. Effects of genetic background and culture conditions on production of herpesvirus-based gene therapy vectors
23. Purification of herpes simplex virus type 1 by density gradient centrifugation and estimation of the sedimentation coefficient of the virion
24. Restricted expression of herpes simplex virus lytic genes during establishment of latent infection by thymidine kinase-negative mutant viruses
25. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir
26. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors
27. The pathogenicity of ribonucleotide reductase-null mutants of herpes simplex virus type 1 in mice
28. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant
29. In vivo expression of β-galactosidase in hippocampal neurons by HSV-mediated gene transfer
30. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence
31. Replication, establishment of latency, and induced reactivation of herpes simplex virus γ1 34.5 deletion mutants in rodent models
32. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma
33. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial
34. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma